Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients-Reference-Cited by-同舟云学术

Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients

Published:2017-05-12 Issue:7 Volume:24 Page:277-281
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Fujita K,Nakai Y,Kawashima A,Ujike T,Nagahara A,Nakajima T,Inoue T,Lee C M,Uemura M,Miyagawa Y,Kaneda Y,Nonomura N

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/cgt201715.pdf

Reference18 articles.

1. Parimi S, Chi KN . Chemotherapy for metastatic castration-sensitive prostatecancer. Int J Urol 2016; 23: 726–733.

2. Schweizer MT, Drake CG . Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014; 33: 641–655.

3. Kaneda Y . Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin Drug Deliv 2010; 7: 1079–1093.

4. Hatano K, Miyamoto Y, Nonomura N, Kaneda Y . Expression of gangliosides, GD1a, and sialyl paragloboside is regulated by NF-κB-dependent transcriptional control of α2,3-sialyltransferase I, II, and VI in human castration-resistant prostate cancer cells. Int J Cancer 2011; 129: 1838–1847.

5. Matsushima-Miyagi T, Hatano K, Nomura M, Li-Wen L, Nishikawa T, Saga K et al. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 2012; 18: 6271–6283.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer;Life;2023-07-01

2. Current status and progress of the development of prostate cancer vaccines;Journal of Cancer;2023

3. Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter;International Journal of Molecular Sciences;2022-10-21

4. Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity;Cancer Immunotherapies;2022

5. Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma;Journal of Controlled Release;2021-06